TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study With Pentasa in Patients With Active Crohn's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria (main):~* Age: at least 18 years~* CD symptoms/onset of disease: ≥ 3 months prior to Visit 1~* Ileal, ileo-colonic or colonic non-stricturing/non-penetrating disease~* A confirmed location of CD (by MRI, X-ray (small bowel and/or colon), and/or endoscopy)~* A Harvey-Bradshaw score between 5 and 12~* Males and non-pregnant, non-nursing women~* Mild to moderate active CD, defined by a CDAI score between 180 and 350~* Active inflammatory disease (C-Reactive Protein (CRP) level above or equal to 5 mg/L), or a biopsy verified inflammation, or fecal calprotectin level above or equal to 50 µg/g)~* Estimated creatinine clearance should be above 75 ml/min~Exclusion Criteria (main):~* Any significant disease or disorder which, in the opinion of the Investigator, may either put the patient at risk because of participation in the trial, or may influence the results of the trial or the patient's ability to participate in the trial~* CD located to the upper gastrointestinal tract and/or jejunal part of the small intestine, and/or to colon below the left colon flexure and/or isolated proctitis and/or anal disease~* Prior treatment resistance to Pentasa (mesalazine)~* Chronic, dominant arthralgia or rheumatoid arthritis~* Palpable abdominal mass~* Biologics (eg anti-TNF-α) must not be used during the trial or 6 months before Visit 1~* Continuous usage of systemic steroids (excluding budesonide) for 3 months or more within the past year~* Positive pregnancy test

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Mesalazine (Type: EXPERIMENTAL): Mesalazine (Mesalamine) 2 g sachet; 6 g daily
- Placebo (Type: PLACEBO_COMPARATOR): Placebo to Mesalazine (Mesalamine) 2 g sachet; 6 g daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: PET CT With HX4 in Cervix Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria~* Histologically confirmed cervix carcinoma (squamous cell carcinoma, adenocarcinoma or adenosquamous carcinoma)~* tumor stages FIGO IB - IVA~* WHO performance status 0 to 2~* Scheduled for primary curative radiotherapy (either or not combined with chemotherapy or hyperthermia)~* No previous surgery to the Cervix~* No previous radiation to the Cervix~* The patient is willing and capable to comply with study procedures~* 18 years or older~* Written informed consent before patient registration~Exclusion criteria~* Recent (\< 3 months) myocardial infarction~* Uncontrolled infectious disease~* Pregnant or breast feeding and/or not willing to take adequate contraceptive measures during the study

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- [18F] HX4 PET imaging (Type: EXPERIMENTAL): injection with \[18F\] HX4 and PET imaging at baseline and after 20 Gy radiotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The DAWN Antivirals Trial for Ambulatory COVID-19 Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Aged 40 years or older;~* At least 2 Covid-19 suggestive symptoms at the time of inclusion, with onset of a maximum of 5 days prior to enrolment, and which cannot be explained by an alternative cause, and defined by the current Sciensano case definition~* Positive result on PCR test or rapid Ag test in the 7 days before inclusion or at the time of inclusion;~* Patient is community dwelling;~* Participant or their proxy is willing and able to give informed consent for participation in the trial;~* Participant is willing to comply with all trial procedures.~Exclusion Criteria:~* Hospital admission is required at the time of possible recruitment;~* Positive PCR or rapid antigen test for SARS-CoV-2 in the last 2 months other than a test at recruitment or in the 7 days prior to recruitment;~* Participating in any other interventional drug clinical study before enrolment in the study;~* Breastfeeding;~* Known severe neurological disorder, especially seizures in the last 12 months;~* Known allergy to camostat or molnupiravir;~* Previous adverse reaction to, or currently taking, camostat or molnupiravir;~* Patients in palliative care;~* Pregnant women or women of childbearing potential who may become pregnant during the trial and don't agree to use any of the effective contraceptive measures lised above;~* Judgement of the recruiting clinician deems participant ineligible.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Camostat (Type: EXPERIMENTAL): 4 x 200 milligram per day for 7 days
- Placebo (Type: PLACEBO_COMPARATOR): 4 x per day for 7 days
- Molnupiravir (Type: EXPERIMENTAL): 2 x 800 milligram per day for 5 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Active Surveillance of 2 Groups of Patients With Localized Prostate Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Localized adenocarcinoma of the prostate with a Gleason score of 3+3 (group I patients) or 3+4 (group II patients)~* Percentage of tumor biopsy invasion \<50% and/or with a size of maximum 8 mm~* With a number of positive tumor biopsies ≤3 (group I patients) or ≤ 5 (group II patients)~* TNM stage T1-2a N0 M0 (group I patients); TNM stage T1-2c N0 M0 (group II patients)~* PSA level at diagnosis \< 10 ng/ml for group I patients; \< 15 ng/ml for group II patients~* Tumor volume negative (group I patients); positive (group II patients)~* Absence of extra-capsular extension~* Life expectancy \> 10 years~* Signed informed consent~* Patient has elected active surveillance as preferred management plan for the prostate cancer~Exclusion Criteria:~* Previous treatment for prostate cancer (including hormonal therapy, radiation therapy, surgery or chemotherapy)~* Patients with hypogonadism

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Epstein + (group I) (Type: ACTIVE_COMPARATOR): Epstein + (Group I) PSA \<10 ng/ml; Gleason 3+3=6; Number of positive biopsies ≤3/12;~% of tumor biopsy invasion \<50% or ≤3mm; mp MRI negative; c-rTNM T1-T2a N0 M0
- Epstein - (group II) (Type: EXPERIMENTAL): Epstein - (Group II) PSA \<15 ng/ml; Gleason score max 3+4; Number of positive biopsies ≤5/12~% of tumor biopsy invasion \<50% and ≤8mm; mp MRI positive; T1-T2c N0 M0

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Oral Rehydration Therapy in Burn Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients aged 18-65 years~* Partial- to full-thickness burn injuries involving 20-65% of total body surface area (TBSA)~Exclusion Criteria:~* Presence of inhalation injury~* Hypotension or shock~* Concomitant serious traumatic injury (i.e. head/ spine trauma)~* Gastric Bypass Surgery~* Small Bowel Obstruction~* Delay in resuscitation \>2 hrs.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Ceralyte 90 (Type: EXPERIMENTAL): Ceralyte® will be administered during the first 24-hours post-burn. Fluid requirements will be calculated according to the Parkland Formula with 50% administered during the first 8 hours and the second 50% administered over the next 16 hours. During the first 2 hours IV fluids will be started at the Parkland goal minus 250cc, which will be administered using Ceralyte via oral, nasogastric (NG), or dobhoff tube. ORT and IV fluids will be monitored with additional doses given hourly. Urine output will be monitored hourly and gastric residuals will be monitored every 2 hours, with adjustments made as needed to ensure adequate fluid resuscitation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: DIM as a Treatment for Thyroid Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adults diagnosed with abnormalities of the thyroid gland suspicious for benign adenoma, or goiterous changes.~Exclusion Criteria:~* Patients who are pregnant, attempting to conceive, or lactating will be excluded due to possible deleterious effects of treatment on fetus/infant. Patients taking oral contraceptives, estrogen therapy, tamoxifin or those with a history of breast cancer will be excluded. Patients with liver disease and those taking statins for hypercholesterolemia will also be excluded to decrease the potential for possible liver toxicity. Any patient with elevated liver enzymes on pretreatment blood screening will be excluded from study participation. Patients with serious systemic diseases such as renal failure, diabetes, blood dyscrasia, coagulopathy, and non-optimized cardiopulmonary disease will be excluded due to the possibility of confounding blood tests screening for toxicity.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): Subjects with proliferative thyroid disease

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of ATG-Fresenius Following a Renal Transplantation, Without Corticosteroids

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~* Signed and dated informed consent form,~* End-stage renal disease,~* Candidates for a first transplantation,~* Re-transplant patients are eligible if a graft loss after transplantation was NOT due to immunological reasons,~* Availability of a heart-beating cadaveric donor up to 70 years of age with a cold ischemia time shorter than 36 hours,~* Male or female patients between 18 to 75 years of age inclusive,~* Patients able to comply with all study related requirements,~* Patients able to receive oral medication,~* Women of childbearing age with a safe contraceptive method throughout the study.~Exclusion Criteria~* Women who are pregnant or breast feeding,~* Known Human Immunodeficiency Virus,~* Hepatitis B Virus or Hepatitis C Virus infection,~* Severe actual viral, bacterial or fungal infection not adequately controlled,~* Patients with anamnestically known hypersensitivity to rabbit immunoglobulin antibodies or positive rabbit immunoglobulin skin test or known allergies to any component of the immunosuppressive drugs per protocol,~* Patients at high immunological risk defined as current PRA \> 25% or historical PRA \> 50%,~* Patients receiving pre-transplant immunosuppressive treatment, including corticosteroids,~* Patients with current or history of malignancies (exception basal cell carcinoma or squamous cell carcinoma in remission),~* Patients with previous transplantation except 1st graft loss due to surgical complications,~* Patients receiving combined transplantation,~* Patients with major organ dysfunctions,~* Serious psychiatric or psychological disorders,~* Pre-transplant thrombocytopenia: \< 50,000 thrombocytes/µl, Pre-transplant leukopenia: \< 2,000 leukocytes/µl,~* Unable or unwilling to comply fully with the protocol,~* Participation in another study of an investigational medicinal product concurrently or within the last 30 days.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Study Group (Type: ACTIVE_COMPARATOR): immunosuppressive treatment consisting of ATG-Fresenius/TAC/MMF or Myfortic
- Control Group (Type: NO_INTERVENTION): immunosuppressive treatment consisting of TAC, MMF or Myfortic, and corticosteroids.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: An Open Trial of Cysteamine Treatment in Schizophrenia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of schizophrenia or schizoaffective disorder~* 18-60 years of age~* Residual symptoms, as defined by both 1 \& 2:~  1. At least one PANSS positive symptom item score \> 4, or at least two items with a score \> 3~ 2. At least one PANSS negative symptom item score \> 4, or at two items with a score \> 3~* No clinically significant change in symptoms for at least one month~* On the same psychotropic medication(s) \> 2 weeks~* Taking a second-generation antipsychotic (olanzapine, risperidone, quetiapine, ziprasidone, aripiprazole, or clozapine)~* Provision of written informed consent~Exclusion Criteria:~* Meets criteria for current major depressive disorder~* Abnormal hepatic function (AST or ALT \> 2.5 X the upper limit of normal, or bilirubin \> 1.5 X the upper limit of normal)~* Abnormal renal function (BUN or creatinine \> 1.5 X the upper limit of normal)~* Presence of any unstable or untreated medical disorder~* Any history of seizure disorder, HIV, or diagnosis of AIDS~* Any abnormal lab test result that is judged to be clinically significant by the investigators~* Pregnancy, breast feeding, or female and of child-bearing potential who is not using any contraceptive method~* Present danger to self or others

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Cystagon, Cysteamine Bitartrate (Type: EXPERIMENTAL): We are examining the safety and efficacy of this medication on the treatment of schizophrenia patients.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Comparing Function, Pain and Return to Work in Conservative Versus Surgical Treated Stable Lateral Malleolar Fractures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Informed Consent as documented by signature (Appendix Informed Consent Form)~* Acute, stable lateral malleolar fracture~Definition of stable:~* Less than 2mm dislocation in a.p., lateral and gravity-stress x-ray~* Medial tibiotalar distance \<4mm and difference \<1mm compared to the superior clear space on the gravity-stress and weight bearing x-ray~* No talar subluxation~* No intraoperative instability (Hook-/Frick-Test)~  * Between 18 and 65 years old~ * Living in Switzerland~ * Working~ * Cognitive and physic ability to follow the study protocol~Exclusion Criteria:~* Instable fractures~* Previous ipsilateral surgery on the ankle or foot~* Pregnancy~* Diabetes mellitus~* Neurologic or vascular impairment~* Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant~* Previous enrolment into the current study~* Enrolment of the investigator, his/her family members, employees and other dependent persons

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Surgical intervention (Type: ACTIVE_COMPARATOR): Open reduction and osteosynthesis by plating is done. Further after treatment is similar to conservative treatment arm.
- Conservative treatment (Type: NO_INTERVENTION): At the first visit a split cast is applied. Afterwards physiotherapy and weightbearing as tolerated is allowed.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: EUS-guided CGN for Inoperable Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. All patients ≥ 18 years old with cytology or histology confirmed pancreatic cancer, or radiologically suggestive of pancreatic cancer ( for patients whom biopsy is impossible)~2. Pain associated with inoperable cancer ( including abdominal pain or back pain, managed according to WHO analgesic ladder, with VAS score ≥4 despite simple analgesics (first 2 steps of WHO analgesic ladder)~3. Inoperability of cancer as demonstrated by EUS, computed tomography (CT) or Positive emission tomography~4. Informed consent available~Exclusion Criteria:~1. Unable to safely undergo EUS for any reason~2. Patient is unable to lie prone for procedure~3. Coagulopathy (prolongation of prothrombin time \> 18 sec) or thrombocytopenia \<80,000 platelets/ml)~4. Previous CPN or other neurolytic block that could affect pancreatic cancer-related pain or had implanted epidural or intrathecal analgesic therapy~5. Another cause for abdominal pain such as pseudocyst, ulcer or other intra-abdominal disorder~6. Allergy to local anaesthesia, contrast, or alcohol~7. Potential patient noncompliance (refusing to follow schedule of events)~8. Active alcohol or other drug use or significant psychiatric illness~9. Expected survival less than 6 weeks

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- EUS-guided celiac ganglion neurolysis (Type: ACTIVE_COMPARATOR): Endoscopic ultrasound guided celiac ganglion neurolysis would be performed
- Percutaneous celiac plexus neurolysis (Type: ACTIVE_COMPARATOR): Percutaneous celiac plexus neurolysis would be performed

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Impact of Sandostatin® Injection Before Axillary Clearance on Lymphocele Formation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Breast cancer, histologically proven Axillary clearance Elective axillary approach Age ≥ 18 years OMS \< 3 Normal hematological and hepatic blood tests Obtaining the signed written consent of the patient~Exclusion Criteria:~Axillary clearance with a mastectomy Metastatic disease Disorder precluding understanding of trial information or informed consent Pregnancy, breastfeeding women Patient is willing and able to comply with the protocol for the duration of the study including all scheduled treatment, visits and examinations No severe or uncontrolled diabetes Known hypersensitivity to Octreotide Patient with vitamin B12 deficiency Anticoagulant treatment History of cardiovascular disease Other product being tested in the 4 weeks prior to the start of treatment Patient has valid health insurance

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sandostatine (Type: EXPERIMENTAL): Injection of Sandostatine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility